Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMerck CEO Robert Davis on Q3 results: Our portfolio sets us up for a good finish to the yearMerck CEO Robert Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business, the company's drug pipeline outlook, and more.
Persons:
Robert Davis, Keytruda
Organizations:
Merck